# Recent trends in the number of pathology samples indicating cancer in Northern Ireland

November 2022 update

#### **Further information**

Further information is available at: www.qub.ac.uk/research-centres/nicr **Phone:** +44 (0)28 9097 6028 **e-mail:** nicr@qub.ac.uk

#### **Acknowledgements**

The Northern Ireland Cancer Registry (NICR) is funded by the Public Health Agency and is based in Queen's University, Belfast.

NICR uses data provided by patients and collected by the health service as part of their care and support.







### **CONTENTS**

	<u>Page</u>
Summary	1
All persons	5
Males	7
Females	9
Ages 0-69	11
Ages 70 and over	13
Bowel cancer	15
Bowel cancer, screening age	17
Lung cancer	19
Female breast cancer	21
Female breast cancer, screening age	23
Prostate cancer	25
Upper gastrointestinal cancer	27
Gynaecological cancer	29
Head & neck cancer	32
Urinary cancer	34
Haematological cancer	37
Malignant melanoma	38
Non-melanoma skin cancer	40
Other cancer	42
Notes	44

### **SUMMARY**

# Recent trends in the number of pathology samples indicating cancer: November 2022


This summary provides an overview of recent trends in the number of pathology samples indicating cancer (excluding non-melanoma skin cancer, NMSC) taken from January 2020 to November 2022 in Northern Ireland.

These trends are contrasted with the annual average number of pathology samples indicating cancer (ex NMSC) during 2017-2019 in order to provide an indication of the potential impact of Covid-19 on diagnostic cancer services.


Data are sourced from the four NHS pathology laboratories in NI (Belfast, Altnagelvin, Antrim, Craigavon), which are usually provided to NICR on a monthly basis. Altnagelvin laboratory is excluded from some analysis as a change in recording systems led to an undercount in the number of reported samples in Jan-Apr 2021.

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 (Excludes Altnagelvin)

From March 2020 to November 2022 the number of pathological samples indicating cancer (ex NMSC) was 4.4% lower than the average number for the same time period in 2017-2019.



From March 2020 to November 2022 there was a 4.2% decrease in the number of samples among males and a 4.6% decrease among females compared to the same time period in 2017-2019. A decrease of 5.3% occurred in the number of samples among those aged 0-69 years, while there was a decrease of 3.2% in the number of samples among those aged 70 and older.




Compared to the annual average in 2017-2019, from March 2020 to November 2022 the number of pathology samples indicating lung cancer decreased by 25.0%. Increases were recorded for female breast cancer and haematological cancer, while decreases of more than 10% were recorded for gynaecological cancer and non-melanoma skin cancer.




#### **RECENT CHANGES IN THE NUMBER OF SAMPLES (Includes Altnagelvin)**

There was a 3.8% increase in the number of pathology samples indicating cancer in the twelve weeks up to 26/11/2022 compared to the average value in the equivalent weeks in 2017-2019.



Note: Date shown refers to the end date of the week in 2022. Data for previous years refers to the equivalent Sat-Sun week in those years



In the twelve weeks up to 26/11/2022 there was a 5.4% increase in the number of samples among males and a 2.7% increase among females compared to the same time period in 2017-2019. A increase of 3.8% occurred in the number of samples among those aged 0-69 years, while there was a increase of 3.7% in the number of samples among those aged 70 and older.


Compared to the annual average in 2017-2019, in the twelve weeks up to 26/11/2022 the number of pathology samples indicating lung cancer decreased by 19.6%. Increases were recorded for bowel cancer, female breast cancer, prostate cancer, upper gastrointestinal cancer, haematological cancer and melanoma, while decreases of more than 10% were recorded for and head and neck cancer.

### ALL PERSONS: CANCER (EX NMSC)

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to November 2022 compared to expected number based on 2017-2019 average

-4.4%




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	1,223	1,257	939	1,104	Jul	1,120	1,026	1,084	1,012
Feb	1,033	1,101	999	1,083	Aug	1,156	1,013	1,085	1,215
Mar	1,138	1,066	1,265	1,212	Sep	1,160	1,169	1,233	1,329
Apr	1,081	687	1,184	1,041	Oct	1,258	1,017	1,107	1,263
May	1,287	779	1,240	1,227	Nov	1,229	1,174	1,279	1,128
Jun	1,159	1,077	1,306	1,108	Dec	1,048	1,150	1,078	
	' <b>,</b>		_						

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average

+3.8%




Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022
10/09/2022	311	334	22/10/2022	345	374
17/09/2022	321	362	29/10/2022	289	311
24/09/2022	337	350	05/11/2022	339	279
01/10/2022	339	379	12/11/2022	313	317
08/10/2022	329	381	19/11/2022	357	326
15/10/2022	319	381	26/11/2022	343	297

\* Average samples per year rounded to the nearest integer.

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to November 2022 compared to expected number based on 2017-2019 average


-4.2%



Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	490	499	359	443	Jul	450	422	449	400
Feb	403	476	419	403	Aug	444	396	421	521
Mar	465	418	553	443	Sep	462	434	496	569
Apr	443	242	468	400	Oct	512	398	421	512
May	522	355	507	515	Nov	502	544	558	416
Jun	469	458	521	423	Dec	412	470	415	

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average




Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022
10/09/2022	311	334	22/10/2022	345	374
17/09/2022	321	362	29/10/2022	289	311
24/09/2022	337	350	05/11/2022	339	279
01/10/2022	339	379	12/11/2022	313	317
08/10/2022	329	381	19/11/2022	357	326
15/10/2022	319	381	26/11/2022	343	297

\* Average samples per year rounded to the nearest integer.

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin


<sup>-4.6%</sup> 



Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	733	758	580	661	Jul	670	604	635	612
Feb	631	625	580	680	Aug	712	617	664	693
Mar	673	648	712	768	Sep	697	735	737	760
Apr	639	445	716	641	Oct	746	619	686	751
May	765	424	733	712	Nov	727	630	721	712
Jun	690	619	785	685	Dec	636	680	663	

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average



Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022
10/09/2022	311	334	22/10/2022	345	374
17/09/2022	321	362	29/10/2022	289	311
24/09/2022	337	350	05/11/2022	339	279
01/10/2022	339	379	12/11/2022	313	317
08/10/2022	329	381	19/11/2022	357	326
15/10/2022	319	381	26/11/2022	343	297


\* Average samples per year rounded to the nearest integer.

### AGED 0-69: CANCER (EX NMSC)

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to November 2022 compared to expected number based on 2017-2019 average

-5.3%




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	741	711	556	608	Jul	640	560	610	595
Feb	624	622	601	621	Aug	681	569	640	707
Mar	683	635	749	721	Sep	677	666	712	765
Apr	634	443	726	545	Oct	715	588	655	701
May	758	456	713	644	Nov	695	680	744	669
Jun	654	604	730	639	Dec	618	699	646	

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average

+3.8%



Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022
10/09/2022	311	334	22/10/2022	345	374
17/09/2022	321	362	29/10/2022	289	311
24/09/2022	337	350	05/11/2022	339	279
01/10/2022	339	379	12/11/2022	313	317
08/10/2022	329	381	19/11/2022	357	326
15/10/2022	319	381	26/11/2022	343	297


\* Average samples per year rounded to the nearest integer.

### AGED 70+: CANCER (EX NMSC)

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to November 2022 compared to expected number based on 2017-2019 average

-3.2%



Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	483	546	383	496	Jul	480	466	474	417
Feb	409	479	398	462	Aug	475	444	445	508
Mar	455	431	516	491	Sep	483	503	521	564
Apr	447	244	458	496	Oct	543	429	452	562
May	529	323	527	583	Nov	534	494	535	459
Jun	504	473	576	469	Dec	430	451	432	•


Number of samples

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average



on 2017-2019 average +3.7%




\* Average samples per year rounded to the nearest integer.

### **BOWEL CANCER**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

<sup>-0.8%</sup> 




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	126	152	106	135	Jul	113	107	137	110
Feb	112	120	125	119	Aug	119	118	139	124
Mar	120	109	140	112	Sep	118	124	142	122
Apr	122	65	151	121	Oct	132	104	146	127
May	137	73	138	129	Nov	141	102	154	142
Jun	125	125	135	123	Dec	115	118	133	

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average

+6.2%




Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022	
10/09/2022	311	334	22/10/2022	345	374	
17/09/2022	321	362	29/10/2022	289	311	
24/09/2022	337	350	05/11/2022	339	279	
01/10/2022	339	379	12/11/2022	313	317	
08/10/2022	329	381	19/11/2022	357	326	
15/10/2022	319	381	26/11/2022	343	297	

 $^{\ast}$  Average samples per year rounded to the nearest integer.

### **BOWEL CANCER (SCREENING AGE)**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

<sup>+1.9%</sup> 




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	60	73	46	63	Jul	46	54	64	49
Feb	51	54	62	54	Aug	51	34	58	64
Mar	53	60	73	46	Sep	52	48	61	41
Apr	50	31	69	54	Oct	63	40	66	50
May	60	26	61	57	Nov	62	46	68	65
Jun	48	62	61	60	Dec	49	56	59	
	' .								

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average

+3.8%



Week sample taken**	2017-2019*	2022	week sample taken**	2017-2019*	2022	
10/09/2022	311	334	22/10/2022	345	374	
17/09/2022	321	362	29/10/2022	289	311	
24/09/2022	337	350	05/11/2022	339	279	
01/10/2022	339	379	12/11/2022	313	317	
08/10/2022	329	381	19/11/2022	357	326	
15/10/2022	319	381	26/11/2022	343	297	


\* Average samples per year rounded to the nearest integer.

### LUNG CANCER

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to November 2022 compared to expected number based on 2017-2019 average

-25.0%




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	83	95	36	53	Jul	84	67	66	40
Feb	75	83	58	57	Aug	88	86	62	68
Mar	79	62	49	59	Sep	97	61	65	77
Apr	79	36	65	69	Oct	88	53	56	66
May	91	59	66	71	Nov	89	64	87	63
Jun	80	84	73	80	Dec	61	60	55	
	' .		_			1			

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average






Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022	
10/09/2022	311	334	22/10/2022	345	374	
17/09/2022	321	362	29/10/2022	289	311	
24/09/2022	337	350	05/11/2022	339	279	
01/10/2022	339	379	12/11/2022	313	317	
08/10/2022	329	381	19/11/2022	357	326	
15/10/2022	319	381	26/11/2022	343	297	

\* Average samples per year rounded to the nearest integer.

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

<sup>+0.2%</sup> 




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	290	245	272	239	Jul	253	213	282	267
Feb	237	246	242	261	Aug	271	232	233	288
Mar	273	235	314	319	Sep	263	292	299	302
Apr	242	187	280	264	Oct	277	265	243	264
May	290	139	320	309	Nov	272	257	274	298
Jun	247	201	343	280	Dec	261	286	255	

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average






Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022
10/09/2022	311	334	22/10/2022	345	374
17/09/2022	321	362	29/10/2022	289	311
24/09/2022	337	350	05/11/2022	339	279
01/10/2022	339	379	12/11/2022	313	317
08/10/2022	329	381	19/11/2022	357	326
15/10/2022	319	381	26/11/2022	343	297

\* Average samples per year rounded to the nearest integer.

### FEMALE BREAST CANCER (SCREENING AGE)

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

<sup>+1.1%</sup> 



Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	155	124	141	109	Jul	127	89	132	116
Feb	125	114	152	124	Aug	145	119	119	142
Mar	133	118	198	144	Sep	134	167	149	145
Apr	115	108	170	107	Oct	147	140	123	121
Мау	135	59	175	134	Nov	135	152	133	152
Jun	117	83	174	148	Dec	135	154	144	

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average

-7.4%

80 70 60 Number of samples 50 40 30 20 10 0 110912022 01/10/2022 081012022 22/10/2022 29/10/2022 05/11/2022 15/10/2022 1010912022 2410912022 121712022 1911/2022 2611/2022 Week sample taken 2017-2019 2022 


Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022
10/09/2022	311	334	22/10/2022	345	374
17/09/2022	321	362	29/10/2022	289	311
24/09/2022	337	350	05/11/2022	339	279
01/10/2022	339	379	12/11/2022	313	317
08/10/2022	329	381	19/11/2022	357	326
15/10/2022	319	381	26/11/2022	343	297

\* Average samples per year rounded to the nearest integer.

### **PROSTATE CANCER**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

<sup>-5.2%</sup> 




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	85	82	47	83	Jul	83	41	48	78
Feb	64	73	53	63	Aug	68	44	59	107
Mar	82	72	124	86	Sep	66	54	92	110
Apr	66	42	70	59	Oct	99	58	65	82
Мау	97	81	77	96	Nov	88	140	96	55
Jun	77	74	97	52	Dec	59	83	70	

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average






Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022	
10/09/2022	311	334	22/10/2022	345	374	
17/09/2022	321	362	29/10/2022	289	311	
24/09/2022	337	350	05/11/2022	339	279	
01/10/2022	339	379	12/11/2022	313	317	
08/10/2022	329	381	19/11/2022	357	326	
15/10/2022	319	381	26/11/2022	343	297	

\* Average samples per year rounded to the nearest integer.

### **UPPER GASTROINTESTINAL CANCER**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

<sup>-3.5%</sup> 




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	41	54	28	39	Jul	42	31	45	34
Feb	40	38	27	37	Aug	39	24	29	43
Mar	42	34	54	48	Sep	47	36	49	46
Apr	39	16	41	26	Oct	37	40	49	45
Мау	39	28	38	42	Nov	41	41	48	36
Jun	38	45	46	37	Dec	33	39	53	
	' <b>.</b>		_						

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average

+7.8%




Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022	
10/09/2022	311	334	22/10/2022	345	374	
17/09/2022	321	362	29/10/2022	289	311	
24/09/2022	337	350	05/11/2022	339	279	
01/10/2022	339	379	12/11/2022	313	317	
08/10/2022	329	381	19/11/2022	357	326	
15/10/2022	319	381	26/11/2022	343	297	

\* Average samples per year rounded to the nearest integer.

### **GYNAECOLOGICAL CANCER**


#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin





Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	101	97	54	75	Jul	94	69	84	92
Feb	84	70	64	96	Aug	104	68	104	84
Mar	91	76	80	78	Sep	90	77	85	74
Apr	77	51	56	73	Oct	98	82	87	101
May	104	60	68	75	Nov	93	90	108	94
Jun	102	70	81	61	Dec	80	89	88	
* 4						i.			

#### <u>CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 BY DETAILED CANCER TYPE - Excluding</u> <u>Altnagelvin</u>



Concontrino	Number of samples (March 2020 to November 2022)				
Cancer type	Expected number*	<b>Recorded number</b>			
Cervical cancer	457	395			
Uterine cancer	1,462	1,204			
Ovarian cancer	883	735			
Other gynaecological cancer	277	260			

\* Based upon average monthly number of samples from 2017-2019.

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average


-2.5%



\* Average samples per year rounded to the nearest integer.

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

<sup>-9.5%</sup> 




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	52	54	44	44	Jul	40	46	31	40
Feb	36	33	66	38	Aug	46	37	38	61
Mar	39	35	60	50	Sep	44	37	39	47
Apr	42	18	42	25	Oct	54	41	38	42
May	50	24	38	50	Nov	51	47	34	44
Jun	51	32	47	57	Dec	50	44	46	

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average






Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022
10/09/2022	311	334	22/10/2022	345	374
17/09/2022	321	362	29/10/2022	289	311
24/09/2022	337	350	05/11/2022	339	279
01/10/2022	339	379	12/11/2022	313	317
08/10/2022	329	381	19/11/2022	357	326
15/10/2022	319	381	26/11/2022	343	297

\* Average samples per year rounded to the nearest integer.

### **URINARY CANCER**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

<sup>-8.3%</sup> 




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	80	73	68	70	Jul	71	85	80	47
Feb	81	72	50	74	Aug	78	69	66	55
Mar	75	78	76	81	Sep	78	68	76	88
Apr	79	40	93	66	Oct	78	54	70	65
May	79	61	105	73	Nov	76	74	75	56
Jun	77	100	81	58	Dec	68	58	60	
		1 1 1				•			

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average

-4.1%




Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022
10/09/2022	311	334	22/10/2022	345	374
17/09/2022	321	362	29/10/2022	289	311
24/09/2022	337	350	05/11/2022	339	279
01/10/2022	339	379	12/11/2022	313	317
08/10/2022	329	381	19/11/2022	357	326
15/10/2022	319	381	26/11/2022	343	297

\* Average samples per year rounded to the nearest integer.

### HAEMATOLOGICAL CANCER


#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

<sup>+2.3%</sup> 



Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	72	97	64	64	Jul	73	83	83	77
Feb	59	81	88	72	Aug	76	73	81	100
Mar	73	85	87	76	Sep	75	89	95	110
Apr	78	49	86	72	Oct	92	67	64	104
May	96	58	90	90	Nov	88	80	82	71
Jun	81	88	102	89	Dec	75	87	63	
* Average sam	ples per year ro	ounded to the r	nearest integer.			1			

#### <u>CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 BY DETAILED CANCER TYPE - Excluding</u> <u>Altnagelvin</u>




Number of samples (March 2020 to November 2022)				
Expected number*	<b>Recorded number</b>			
2,016	2,201			
339	263			
210	177			
30	28			
	Expected number* 2,016 339 210			

\* Based upon average monthly number of samples from 2017-2019.

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average




\* Average samples per year rounded to the nearest integer.

### MELANOMA

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

# Percentage change from March 2020 to November 2022 compared to expected number based on 2017-2019 average

-0.5%




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	38	50	29	46	Jul	44	22	33	33
Feb	38	43	31	42	Aug	36	39	44	62
Mar	40	54	34	45	Sep	44	38	46	70
Apr	40	29	44	49	Oct	49	21	52	60
May	41	17	36	48	Nov	47	48	64	48
Jun	38	27	46	43	Dec	38	32	26	
			_			•			

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average

+22.8%




Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022
10/09/2022	311	334	22/10/2022	345	374
17/09/2022	321	362	29/10/2022	289	311
24/09/2022	337	350	05/11/2022	339	279
01/10/2022	339	379	12/11/2022	313	317
08/10/2022	329	381	19/11/2022	357	326
15/10/2022	319	381	26/11/2022	343	297

\* Average samples per year rounded to the nearest integer.

### NON-MELANOMA SKIN CANCER

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

<sup>-22.5%</sup> 




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	652	759	398	466	Jul	514	383	367	374
Feb	561	577	405	452	Aug	549	374	398	500
Mar	550	495	470	525	Sep	641	488	532	566
Apr	520	95	504	461	Oct	663	494	483	623
May	599	236	423	541	Nov	692	577	538	614
Jun	594	436	497	495	Dec	499	410	408	•

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average

-7.9%




Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022	
10/09/2022	311	334	22/10/2022	345	374	
17/09/2022	321	362	29/10/2022	289	311	
24/09/2022	337	350	05/11/2022	339	279	
01/10/2022	339	379	12/11/2022	313	317	
08/10/2022	329	381	19/11/2022	357	326	
15/10/2022	319	381	26/11/2022	343	297	

\* Average samples per year rounded to the nearest integer.

### **OTHER CANCER**

#### CHANGE IN NUMBER OF SAMPLES SINCE MARCH 2020 - Excluding Altnagelvin

<sup>+0.8%</sup> 




Month sample taken**	2017- 2019*	2020	2021	2022	Month sample taken**	2017- 2019*	2020	2021	2022
Jan	106	86	103	104	Jul	91	110	90	80
Feb	84	83	94	94	Aug	91	75	78	87
Mar	92	105	113	105	Sep	91	133	90	108
Apr	87	51	86	85	Oct	106	106	93	97
May	95	70	118	91	Nov	101	97	97	88
Jun	90	94	107	95	Dec	89	81	89	
Feb Mar Apr May	84 92 87 95	83 105 51 70	94 113 86 118	94 105 85 91	Aug Sep Oct Nov	91 91 106 101	75 133 106 97	78 90 93 97	87 108 97

#### **RECENT CHANGES IN NUMBER OF SAMPLES - Including Altnagelvin**

#### Percentage change in the twelve weeks up to 26/11/2022 compared to expected number based on 2017-2019 average





Week sample taken**	2017-2019*	2022	Week sample taken**	2017-2019*	2022
10/09/2022	311	334	22/10/2022	345	374
17/09/2022	321	362	29/10/2022	289	311
24/09/2022	337	350	05/11/2022	339	279
01/10/2022	339	379	12/11/2022	313	317
08/10/2022	329	381	19/11/2022	357	326
15/10/2022	319	381	26/11/2022	343	297

\* Average samples per year rounded to the nearest integer.

#### 1. NMSC: Non-melanoma skin cancer

2. Data is sourced from the four NHS pathology laboratories in Northern Ireland (Altnagelvin, Antrim, Belfast, Craigavon), which is provided to the NI Cancer Registry on a monthly basis. It does not include information on pathology samples processed by private laboratories.

3. Figures represent the number of pathology samples that indicated a malignant tumour and had this result coded and recorded by the end of November 2022. Due to potential reporting delays, pathology data from the month following November 2022 are used in compiling the presented results.

4. Assignment of week number is based upon a Sunday to Saturday week. The week ending label used in graphs and tables is based upon the date of the end of the week (a Saturday) in 2021-2022. This is compared with the equivalent Sunday-Saturday week in 2017-2019, although the actual date ending this week in 2017-2019 will differ.

5. Cancer types are defined as follows:

Bowel cancer: Includes colon, rectum and rectosigmoid junction (ICD10 codes: C18-C20).

Lung cancer: Includes lung and trachea (ICD10 codes: C33-C34).

Breast cancer: Includes female breast only (ICD10 codes: C50).

Prostate cancer: (ICD10 codes: C61).

**Gynaecological cancer:** Includes uterus, ovary, cervix, vulva, vagina, placenta and other female genital (ICD10 codes: C51-C58).

Upper GI cancer: Includes oesophagus and stomach (ICD10 codes: C15, C16).

**Head and neck cancer:** Includes lip, tongue, mouth, parotid & salivary glands, tonsil, oropharynx, nasopharynx, pyriform sinus, hypopharynx, nasal cavity, middle ear, sinuses and larynx (ICD10 codes: C00-C14, C30-C32).

**Urinary cancer:** Includes kidney, renal pelvis, ureter, bladder and other urinary (ICD10 codes: C64-C68). **Haematological cancer:** Includes lymphoma (all types), leukaemia (all types), myeloma, malignant immunoproliferative disease and other lymphoid and haematopoietic (ICD10 codes: C81-C96). **Melanoma:** (ICD10 code: C43).

Non-melanoma skin cancer (NMSC): (ICD10 code: C44).

**Other cancer:** Includes cancers of small intestine, anus, liver, pancreas, gallbladder, thymus, bone, mesothelioma, soft tissue, penis, testis, eye, brain, endocrine system and thyroid (ICD10 codes: C16, C21-C26, C37-C41, C45-C49, C60, C62, C63, C69-C75). Excludes cancer of unknown primary.